according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Letermovir Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Piercetown

A86 HD21 Dunboyne, Ireland

Telephone : 908-740-4000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2 Specific target organ toxicity - repeated

exposure, Category 2

H361d: Suspected of damaging the unborn child. H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

H373 May cause damage to organs through prolonged

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

or repeated exposure.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Letermovir

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Components			
Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Letermovir	917389-32-3	Repr. 2; H361d	>= 30 - < 50
		STOT RE 2; H373	
		(Liver, spleen, Blood)	

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

 Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dusts non-specific 4 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable

dust)

Basis: IE OEL

10 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable

dust)

Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
Letermovir	917389-32- 3	TWA	0.4 mg/m3 (OEB 2)	Internal
Silicon dioxide	7631-86-9	OELV - 8 hrs (TWA) (Respira- ble dust)	2.4 mg/m3 (Silica)	IE OEL
		OELV - 8 hrs (TWA) (inhalable dust)	6 mg/m3 (Silica)	IE OEL
Magnesium stea- rate	557-04-0	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Silicon dioxide	Workers	Inhalation	Long-term systemic effects	4 mg/m3

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Letermovir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Letermovir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 59340-00027 Date of first issue: 16.02.2015 4.3

Result: negative

Genotoxicity in vivo Test Type: Mammalian erythrocyte micronucleus test (in vivo

> cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Letermovir:

Effects on fertility Test Type: Fertility/early embryonic development

> Species: Rat, female Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: LOAEL: 180 mg/kg body weight

Result: No effects on fertility

Remarks: The significance of these findings for humans is not

certain.

Test Type: Fertility/early embryonic development

Species: Monkey, male Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Developmental Toxicity: LOAEL: 250 mg/kg body weight

Result: Embryo-foetal toxicity Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: LOAEL: 225 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.,

Abortion

Remarks: Maternal toxicity observed.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Letermovir:

Exposure routes : Ingestion

Target Organs : Liver, spleen, Blood

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Letermovir:

Species : Mouse

NOAEL : 40 mg/kg

LOAEL : 100 mg/kg

Application Route : Oral

Exposure time : 13 Weeks

Target Organs : Liver, spleen

Species : Rat

NOAEL : 150 mg/kg Application Route : Oral Exposure time : 26 Weeks

Remarks : No significant adverse effects were reported

 Species
 : Monkey

 NOAEL
 : 100 mg/kg

 LOAEL
 : 200 - 250 mg/kg

Application Route : Oral
Exposure time : 39 Weeks
Target Organs : Kidney

Species : Rat
NOAEL : 60 mg/kg
LOAEL : 180 mg/kg
Exposure time : 13 Weeks

Target Organs : Testis, Blood, Liver, spleen, Immune system

Species : Monkey
NOAEL : 30 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

Target Organs : Blood

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Letermovir:

Ingestion : Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizzi-

ness, Fatigue, Back pain, Oedema, Rash, muscle pain

SECTION 12: Ecological information

12.1 Toxicity

Components:

Letermovir:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 16 mg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

: EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.3
 28.09.2024
 59340-00027
 Date of first issue: 16.02.2015

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 972 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 29.6 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 1 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 1.2 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

12.2 Persistence and degradability

Components:

Letermovir:

Biodegradability : Result: rapidly degradable

Biodegradation: 50 % Exposure time: 6.7 d

12.3 Bioaccumulative potential

Components:

Letermovir:

Partition coefficient: n-

log Pow: 2.29

octanol/water

12.4 Mobility in soil

Components:

Letermovir:

Distribution among environ-

: log Koc: 3.46

mental compartments

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

Not applicable

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone : Not applicable

layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia-

ment and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations,

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated

exposure if swallowed.

Full text of other abbreviations

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified;

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Letermovir Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.3 28.09.2024 59340-00027 Date of first issue: 16.02.2015

NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://ocha.guropa.gu/

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Repr. 2 H361d Calculation method STOT RE 2 H373 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN